Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability-Reference-Cited by-同舟云学术

Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability

Published:2015-04-03 Issue:5 Volume:6 Page:596-601
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Pettersson Martin¹,Johnson Douglas S.¹,Humphrey John M.²,Butler Todd W.²,am Ende Christopher W.²,Fish Benjamin A.²,Green Michael E.¹,Kauffman Gregory W.²,Mullins Patrick B.²,O’Donnell Christopher J.²,Stepan Antonia F.¹,Stiff Cory M.²,Subramanyam Chakrapani²,Tran Tuan P.²,Vetelino Beth Cooper²,Yang Eddie²,Xie Longfei²,Bales Kelly R.¹,Pustilnik Leslie R.²,Steyn Stefanus J.¹,Wood Kathleen M.¹,Verhoest Patrick R.¹

Affiliation:

1. Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States

2. Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00070

Reference33 articles.

1. 2013 Alzheimer's disease facts and figures

2. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics